Meanwhile, trouble may be brewing in the statin market

While most of the fuss in the pharma industry concerns the COX-2 inhibitors (Vioxx™, Celebrex™, Bextra™), there’s news in the “statin”: world also. Last year, study after study was showing more and more benefits to the statins. The only glitch was rhabdomylosis, a potentially fatal condition involving disintegration of muscle tissue. (Most cases involve mild muscle weakness.) However, a new, large study has experts scratching their heads. Seems Lipitor™ does its job (lowering LDL(low-density lipoprotein) cholesterol) very well, and even lowers risk of death due to cardiovascular problems. However, risk of non-cardiovascular deaths is up fairly high in the treatment group.

Time to perk your ears up and listen.

%d bloggers like this: